Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika – Branchentrends und Prognose bis 2031

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika – Branchentrends und Prognose bis 2031

  • Pharmaceutical
  • Publish Reports
  • Feb 2024
  • MEA
  • 350 Seiten
  • Anzahl der Tabellen: 771
  • Anzahl der Abbildungen: 28

>Markt für Impfstoffe für Tiere und Menschen im Nahen Osten und in Afrika, nach Typ (für Menschen und Tiere), Endverbraucher (Krankenhäuser, Kliniken und andere), Vertriebskanal (direkte Ausschreibungen, Einzelhandelsverkäufe und andere) – Branchentrends und Prognose bis 2031.

Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika

Marktanalyse und Einblicke für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika

Die Prävalenz von Infektionskrankheiten nimmt weltweit zu, und Grippe und bakterielle Infektionskrankheiten nehmen rasant zu, was das Marktwachstum ankurbelt. Die leichten Nebenwirkungen, wie Rötung, Schmerzen oder Schwellung an der Injektionsstelle, können allergische Reaktionen umfassen, und Reaktionen sind äußerst selten und werden voraussichtlich das Marktwachstum beeinträchtigen.

Markt für Tier- und Humanimpfstoffe im Nahen Osten und in AfrikaMarkt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika

Laut einer Analyse von Data Bridge Market Research wird der Markt für Impfstoffe für Tiere und Menschen im Nahen Osten und in Afrika voraussichtlich von 3.480.103,50 Tausend USD im Jahr 2023 auf 5.358.452,80 Tausend USD im Jahr 2031 anwachsen und im Prognosezeitraum zwischen 2024 und 2031 eine durchschnittliche jährliche Wachstumsrate (CAGR) von 5,6 % aufweisen.

Berichtsmetrik

Details

Prognosezeitraum

2024 bis 2031

Basisjahr

2023

Historische Jahre

2022 (anpassbar auf 2016–2021)

Quantitative Einheiten

Umsatz in Tausend USD

Abgedeckte Segmente

Typ (Mensch und Tier), Endverbraucher (Krankenhäuser, Kliniken und andere), Vertriebskanal (Direktausschreibungen, Einzelhandelsverkäufe und andere)

Abgedeckte Länder

Saudi-Arabien, Ägypten, Vereinigte Arabische Emirate, Israel, Iran, Irak, Oman, Kuwait, Katar, Bahrain, Jemen, Jordanien, Libanon, Palästina, Rest des Nahen Ostens, Südafrika, Nigeria, Äthiopien, Tansania, Kenia, Algerien, Ghana, Mosambik , Uganda, Demokratische Republik Kongo, Sudan, Marokko, Angola, Madagaskar, Malawi, Sambia, Elfenbeinküste, Kamerun, Simbabwe, Libyen, Tschad, Botswana, Namibia, Lesotho, Mauritius, Eswatini, Komoren, Seychellen und Rest Afrikas

Abgedeckte Marktteilnehmer

GSK plc., Merck & Co., Inc., Sanofi, Boehringer Ingelheim International GmbH., Ceva, ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC (PTY) LTD, MCI Santé Animale, Biogénesis Bagó und HESTER BIOSCIENCES LIMITED unter anderem

Marktdefinition

Impfstoffe sind Produkte, die das Immunsystem des Einzelnen stimulieren, um Immunität gegen eine bestimmte Krankheit zu erzeugen. Impfstoffe funktionieren nach dem Prinzip des Gedächtnisses und der Wiedererkennung. Wenn abgeschwächte oder abgetötete Mikroben in einen Körper injiziert werden, bewirken diese Mikroben, dass B-Zellen, die Gedächtniszellen des Immunsystems, den Erreger erkennen, und wenn derselbe Erreger den Körper in Zukunft angreift, arbeitet das Immunsystem gegen ihn. Es wurden Impfstoffe für mehrere Arten von Infektionskrankheiten entdeckt, darunter Pneumokokken-Erkrankungen, Masern, Mumps, Röteln, Hepatitis, Grippe, Typhus, Windpocken und Tollwut.

Marktdynamik für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika

In diesem Abschnitt geht es um das Verständnis der Markttreiber, Chancen, Herausforderungen und Einschränkungen. All dies wird im Folgenden ausführlich erläutert:

Treiber

  • Wachsende Impfprogramme und -kampagnen

Die Umsetzung eines umfassenden Impfprogramms in den Ländern des Nahen Ostens und Afrikas ist von entscheidender Bedeutung, um die öffentliche Gesundheit zu verbessern und die Ausbreitung von Infektionskrankheiten zu verhindern. Um den Erfolg solcher Initiativen sicherzustellen, ist es wichtig, umfassende Aufklärungskampagnen durchzuführen. Aufgrund der steigenden Zahl chronischer Krankheiten nehmen Impfprogramme und -kampagnen weltweit zu. Es besteht dringender Bedarf, das Bewusstsein für Impfungen zu schärfen. Dies kann durch die Einführung mehrerer Kampagnen und Programme erreicht werden, da Hepatitis, Diphtherie, Keuchhusten und Kinderlähmung sowie andere Infektionskrankheiten in der Umwelt weit verbreitet sind. Es wurde berichtet, dass die Zahl der Impfprogramme mit der Zunahme von Infektionskrankheiten zunimmt. Gleichzeitig nimmt auch die Durchimpfungsrate weltweit zu, um schwächende Krankheiten zu bekämpfen.

  • Zunehmende Verbreitung chronischer Erkrankungen

Die Verbreitung von Infektionskrankheiten nimmt weltweit zu, und Grippe und bakterielle Infektionskrankheiten nehmen rasant zu. Diese zunehmende Zahl an Infektionskrankheiten hat die Notwendigkeit einer Krankheitsvorbeugung geschaffen, die durch Impfung oder Immunisierung verhindert werden kann. Massenimpfungen sind dringend erforderlich, da die Zahl der Krankheiten stark zunimmt. Massenimpfungen erfordern eine große Menge an Impfstoffen und dürften daher dem Markt ein lukratives Wachstum bescheren. Die weltweite Verbreitung zunehmender chronischer Krankheiten hat die Nachfrage nach Impfstoffen deutlich erhöht und damit den Impfstoffmarkt erweitert. Als Reaktion auf diese eskalierende gesundheitliche Herausforderung wird die präventive Rolle von Impfstoffen bei der Verringerung der Häufigkeit und Schwere verschiedener chronischer Krankheiten zunehmend anerkannt.

Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika

Gelegenheit

  • Strategische Initiativen und Entscheidungen der Marktteilnehmer

Die Marktteilnehmer ergreifen verschiedene strategische Initiativen auf dem Impfstoffmarkt, die unter anderem Expansion, Zusammenarbeit und Akquisitionen umfassen. Diese Initiativen ermöglichen es ihnen, das Produktportfolio des Unternehmens zu erweitern, was zu einer Marktexpansion führt und somit die Produktnachfrage bei den Kunden steigert, was den Marktteilnehmern letztendlich ermöglicht, maximale Umsätze zu erzielen. Ein entscheidender Aspekt sind kontinuierliche Investitionen in Forschung und Entwicklung, um Innovationen zu entwickeln und neue Impfstoffe einzuführen, die auf neu auftretende Gesundheitsbedrohungen reagieren. Kooperationen mit Forschungseinrichtungen, Regierungsbehörden und Gesundheitsorganisationen im Nahen Osten und Afrika helfen dabei, kollektives Fachwissen und Ressourcen zu nutzen.

Diese strategischen Initiativen werden von führenden Marktteilnehmern ergriffen und zielen darauf ab, die Geschäftsabläufe zu verbessern und die Rentabilität des Marktes zu steigern, da die Nachfrage nach wirksamen und neuartigen Impfstoffen weltweit steigt.

Einschränkungen/Herausforderungen

  • Keine Verfügbarkeit registrierter Impfstoffe auf dem Markt

Die strengen behördlichen Zulassungen und zeitaufwändigen Entwicklungsverfahren für die Impfstoffe sind einige der Faktoren, die für die Nichtverfügbarkeit registrierter Impfstoffe verantwortlich sind. Die Nichtverfügbarkeit eines registrierten Impfstoffs kann erhebliche Auswirkungen auf die öffentliche Gesundheit haben und Herausforderungen bei der Prävention und Bekämpfung von Krankheiten mit sich bringen. Wenn ein Impfstoff nicht verfügbar ist, kann dies zu einer erhöhten Anfälligkeit für Infektionskrankheiten, potenziellen Ausbrüchen und einem höheren Risiko schwerer gesundheitlicher Folgen für die Bevölkerung führen. Die Lösung der Nichtverfügbarkeit eines registrierten Impfstoffs erfordert eine Kombination von Bemühungen von Aufsichtsbehörden, Pharmaunternehmen und Gesundheitssystemen. Die Aufsichtsbehörden haben Schwierigkeiten bei der Bewertung, Zulassung, Kontrolle und Überwachung von Impfstoffen. Die weltweite Versorgung mit Impfstoffen verzögert sich aufgrund dieser Vorschriften.

  • Schädliche Nebenwirkungen durch Impfungen

Der Impfstoff ist ein medizinisches Produkt und hilft bei der Vorbeugung verschiedener Krankheiten. Manchmal treten jedoch Nebenwirkungen aufgrund der Verwendung der Impfstoffe auf. Einige davon sind leichte Nebenwirkungen wie Rötung, Schmerzen oder Schwellung an der Injektionsstelle. Die überwiegende Mehrheit der Nebenwirkungen von Impfstoffen ist leicht und vorübergehend, und der Nutzen der Impfung bei der Vorbeugung schwerer Krankheiten überwiegt die Risiken bei weitem. Dazu können allergische Reaktionen gehören, obwohl schwere allergische Reaktionen äußerst selten sind. Darüber hinaus können Impfstoffe, wie jeder medizinische Eingriff, seltene, aber schwerwiegende Nebenwirkungen wie das Guillain-Barré-Syndrom (GBS) oder Thrombosen haben. Die Nebenwirkungen der Impfstoffe sind jedoch selten, aber lebensbedrohlich.

Jüngste Entwicklungen

  • Im Januar 2023 erhielt Senvelgo, die neueste Innovation von Boehringer Ingelheim, den renommierten Preis „Animal Health Best New Product for Companion Animals“. Diese Auszeichnung würdigt Senvelgo für seinen bemerkenswerten Beitrag zur Vereinfachung und Verbesserung der Behandlung diabetischer Katzen. Boehringer Ingelheims Engagement für Innovation zeigt sich in Senvelgo, das eine Lösung bietet, die nicht nur einfach und sicher, sondern auch äußerst praktisch für Katzenpatienten und ihre Pfleger ist.
  • Im Jahr 2023 erhielt Merck & Co., Inc. von der US-amerikanischen Food and Drug Administration (FDA) die Zulassung für KEYTRUDA, seine Anti-PD-1-Therapie, in Kombination mit Chemoradiotherapie (CRT) zur Behandlung von Patienten mit Gebärmutterhalskrebs im Stadium III-IVA gemäß FIGO 2014. Diese Zulassung basiert auf positiven Ergebnissen der Phase-3-Studie KEYNOTE-A18, in der KEYTRUDA in Kombination mit CRT eine 41-prozentige Verringerung des Risikos eines Fortschreitens der Krankheit oder des Todes im Vergleich zu einem Placebo plus CRT zeigte. Das mediane progressionsfreie Überleben (PFS) wurde in keiner der Gruppen erreicht. Dies ist die dritte Indikation für KEYTRUDA bei Gebärmutterhalskrebs, was seine Wirksamkeit unterstreicht, und es ist die 39. Gesamtindikation für KEYTRUDA in den Vereinigten Staaten. Dieser Meilenstein unterstreicht das Engagement von Merck, Behandlungsmöglichkeiten für Patienten mit verschiedenen Krebsarten voranzutreiben
  • Im Juli 2023 kündigte Biogenesis Bago BIOAFTOGEN bei der Ernährungs- und Landwirtschaftsorganisation der Vereinten Nationen (FAO) an. Dies ist ein historischer Moment, da BIOAFTOGEN der erste MKS-Impfstoff ist, der eine solche Vorqualifizierung erhält. Dieser Erfolg stärkt die Position des Unternehmens als weltweit führendes Unternehmen in der MKS-Prävention und unterstreicht sein Engagement für die Zusammenarbeit mit führenden technischen und wissenschaftlichen Organisationen, um zur Lebensmittelsicherheit und Tiergesundheit weltweit beizutragen.
  • Im November 2020 präsentierte GSK plc. zusammen mit Medicines for Malaria Venture positive Daten (TEACH-Studie) zu Tafenoquin zur Behandlung von Plasmodium vivax-Malaria bei Kindern und Jugendlichen. Während der viermonatigen Untersuchung zeigten 95 % der 60 Probanden der Studie keine Anzeichen von Plasmodium vivax-Malaria. Die Ergebnisse wurden im Rahmen einer virtuellen Jahrestagung der American Society of Tropical Medicine & Hygiene 2020 vorgestellt. Dies hat dem Unternehmen geholfen, das Produkt zur Behandlung von Malaria voranzutreiben und Beweise für die Wirksamkeit seines Produkts zu liefern.
  • Im November 2020 erhielt Sanofi von der Europäischen Kommission die Zulassung für Supemtek (quadrivalenter rekombinanter Grippeimpfstoff) zur Vorbeugung von Grippeerkrankungen bei Erwachsenen ab 18 Jahren. Diese Zulassung half dem Unternehmen, sein Produktportfolio im Bereich Impfstoffe weiterzuentwickeln und seine Verankerung auf dem europäischen Impfstoffmarkt zu stärken.

Marktumfang für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika

Der Markt für Tier- und Humanimpfstoffe im Nahen Osten und Afrika ist in drei wichtige Segmente unterteilt, basierend auf Typ, Endverbraucher und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen dabei, Nischenwachstumsbereiche und Strategien zur Marktbearbeitung zu analysieren und Ihre wichtigsten Anwendungsbereiche und die Unterschiede in Ihren Zielmärkten zu bestimmen.

Typ

  • Menschlich
  • Tier

Auf der Grundlage des Typs ist der Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika in die Märkte für Menschen und Tiere unterteilt.

Endbenutzer

  • Krankenhäuser
  • Kliniken
  • Sonstiges

Auf der Grundlage des Endverbrauchers ist der Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika in Krankenhäuser, Kliniken und andere unterteilt.

Vertriebskanal

  • Direkte Ausschreibungen
  • Einzelhandelsumsätze
  • Sonstiges

Auf der Grundlage der Vertriebskanäle ist der Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika in Direktausschreibungen, Einzelhandelsverkäufe und Sonstiges unterteilt.

Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika

Regionale Analyse/Einblicke zum Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika

Der Markt für Tiere und Impfstoffe im Nahen Osten und in Afrika ist in drei wichtige Segmente unterteilt: Typ, Endbenutzer und Vertriebskanal.

Die in diesem Marktbericht behandelten Länder sind Saudi-Arabien, Ägypten, Vereinigte Arabische Emirate, Israel, Iran, Irak, Oman, Kuwait, Katar, Bahrain, Jemen, Jordanien, Libanon, Palästina, der übrige Nahe Osten, Südafrika, Nigeria, Äthiopien und Tansania , Kenia, Algerien, Ghana, Mosambik, Uganda, Demokratische Republik Kongo, Sudan, Marokko, Angola, Madagaskar, Malawi, Sambia, Elfenbeinküste, Kamerun, Simbabwe, Libyen, Tschad, Botswana, Namibia, Lesotho, Mauritius, Eswatini, Komoren , Seychellen und übriges Afrika.

Südafrika wird voraussichtlich den afrikanischen Markt für Tiere und Impfstoffe dominieren, da die Regierung das Land zunehmend unterstützt und finanziert. Saudi-Arabien wird voraussichtlich den Markt für Tiere und Impfstoffe im Nahen Osten dominieren, da dort Immunisierungsprogramme und -kampagnen zunehmen.

Der Länderabschnitt des Berichts enthält auch individuelle marktbeeinflussende Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neuverkäufe, Ersatzverkäufe, demografische Daten des Landes, Regulierungsgesetze und Import-/Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit regionaler Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.

Wettbewerbsumfeld und Marktanteilsanalyse für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika

Die Wettbewerbslandschaft des Marktes für Tier- und Humanimpfstoffe im Nahen Osten und Afrika bietet Einzelheiten nach Wettbewerbern. Zu den enthaltenen Einzelheiten gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -anlagen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktzulassungen, Produktbreite und -breite, Anwendungsdominanz, Produkttyp-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens auf den Markt für Tier- und Humanimpfstoffe im Nahen Osten und Afrika.

Zu den wichtigsten Akteuren auf dem Markt für Tier- und Humanimpfstoffe im Nahen Osten und in Afrika zählen unter anderem GSK plc., Merck & Co., Inc., Sanofi, Boehringer Ingelheim International GmbH., Ceva, ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC (PTY) LTD, MCI Santé Animale, Biogénesis Bagó und HESTER BIOSCIENCES LIMITED.


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 REGULATORY SCENARIO

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS

6.1.2 GROWING PREVALENCE OF CHRONIC CONDITIONS

6.1.3 PRODUCTION OF NEW VACCINES IN THE HEALTHCARE MARKET

6.1.4 INCREASING GOVERNMENT SUPPORT AND FUNDING

6.2 RESTRAINTS

6.2.1 UNAVAILABILITY OF REGISTERED VACCINES IN THE MARKET

6.2.2 HIGH COST AND DIFFERENCES IN PRICING OF THE VACCINES

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS

6.3.2 RISING PREVALENCE OF PIPELINE PRODUCTS

6.3.3 EMPHASIZING THE ROLE OF VACCINATION IN INDIVIDUAL AND COMMUNITY

6.4 CHALLENGES

6.4.1 HARMFUL SIDE EFFECTS CAUSED BY VACCINATION

6.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS

7 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY TYPE

7.1 OVERVIEW

7.2 HUMAN

7.2.1 HUMAN PAPILLOMAVIRUS (HPV)

7.2.1.1 CERVICAL CANCER

7.2.1.2 OROPHARYNGEAL CANCER

7.2.1.3 ANAL CANCER

7.2.1.4 VULVAR AND VAGINAL CANCER

7.2.1.5 PENILE CANCER

7.2.1.6 OTHERS

7.2.2 PNEUMOCOCCAL VACCINE (PCV)

7.2.3 DTAP VACCINE

7.2.4 ROTAVIRUS VACCINE

7.2.5 INFLUENZA VACCINE

7.2.6 OTHERS

7.3 ANIMAL

7.3.1 BRUCELLOSIS

7.3.1.1 LIVE

7.3.1.2 INACTIVATED

7.3.1.2.1 CATTLE

7.3.1.2.2 CAPRINE

7.3.1.2.3 OVINE

7.3.2 FOOT AND MOUTH

7.3.2.1 INACTIVATED

7.3.2.2 LIVE

7.3.2.2.1 CATTLE

7.3.2.2.2 SHEEP AND GOAT

7.3.2.2.3 PIGS

7.3.2.2.4 OTHERS

7.3.3 AFRICAN HORSE SICKNESS

7.3.3.1 LIVE

7.3.3.2 INACTIVATED

7.3.3.2.1 HORSE

7.3.3.2.2 DONKEY

7.3.3.2.3 MULES

7.3.4 RIFT VALLEY FEVER

7.3.4.1 LIVE

7.3.4.2 INACTIVATED

7.3.4.2.1 SMITHBURN STRAIN BASED VACCINE

7.3.4.2.2 ALUMINUM HYDROXIDE GEL AS ADJUVANT BASED VACCINE

7.3.4.2.3 Others

8 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITAL

8.2.1 HUMAN HOSPITALS

8.2.2 VETERINARY HOSPITALS

8.3 CLINICS

8.3.1 SPECIALTY CLINICS

8.3.2 VETERINARY CLINICS

8.4 OTHERS

8.4.1 ANIMAL HUSBANDRY

8.4.2 PET SHOPS

8.4.3 OTHERS

9 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 DIRECT TENDERS

9.3 RETAIL SALES

9.4 OTHERS

10 MIDDLE EAST & AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY COUNTRY

10.1 MIDDLE EAST & AFRICA

10.2 MIDDLE EAST

10.2.1 SAUDI ARABIA

10.2.2 EGYPT

10.2.3 U.A.E.

10.2.4 ISRAEL

10.2.5 IRAN

10.2.6 IRAQ

10.2.7 OMAN

10.2.8 KUWAIT

10.2.9 QATAR

10.2.10 BAHRAIN

10.2.11 YEMEN

10.2.12 JORDAN

10.2.13 LEBANON

10.2.14 PALESTINE

10.2.15 REST OF MIDDLE EAST

10.3 AFRICA

10.3.1 SOUTH AFRICA

10.3.2 NIGERIA

10.3.3 ETHIOPIA

10.3.4 TANZANIA

10.3.5 KENYA

10.3.6 ALGERIA

10.3.7 GHANA

10.3.8 MOZAMBIQUE

10.3.9 UGANDA

10.3.10 DEMOCRATIC REPUBLIC OF CONGO

10.3.11 SUDAN

10.3.12 MOROCCO

10.3.13 ANGOLA

10.3.14 MADAGASCAR

10.3.15 MALAWI

10.3.16 ZAMBIA

10.3.17 IVORY COAST

10.3.18 CAMEROON

10.3.19 ZIMBABWE

10.3.20 LIBYA

10.3.21 CHAD

10.3.22 BOTSWANA

10.3.23 NAMIBIA

10.3.24 LESOTHO

10.3.25 MAURITIUS

10.3.26 ESWATINI

10.3.27 COMOROS

10.3.28 SEYCHELLES

10.3.29 REST OF AFRICA

11 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, COMPANY LANDSCAPE

11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

12 SWOT ANALYSIS

13 COMPANY PROFILES

13.1 GSK PLC.

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 PRODUCT PORTFOLIO

13.1.4 RECENT DEVELOPMENTS

13.2 MERCK & CO., INC.

13.2.1 COMPANY SNAPSHOT

13.2.2 REVENUE ANALYSIS

13.2.3 PRODUCT PORTFOLIO

13.2.4 RECENT DEVELOPMENTS

13.3 SANOFI

13.3.1 COMPANY SNAPSHOT

13.3.2 REVENUE ANALYSIS

13.3.3 PRODUCT PORTFOLIO

13.3.4 RECENT DEVELOPMENTS

13.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

13.4.1 COMPANY SNAPSHOT

13.4.2 PRODUCT PORTFOLIO

13.4.3 RECENT DEVELOPMENT

13.5 CEVA SANTÉ ANIMALE

13.5.1 COMPANY SNAPSHOT

13.5.2 PRODUCT PORTFOLIO

13.5.3 RECENT DEVELOPMENT

13.6 BIOGENESIS BAGO SA

13.6.1 COMPANY SNAPSHOT

13.6.2 PRODUCT PORTFOLIO

13.6.3 RECENT DEVELOPMENT

13.7 HESTER BIOSCIENCES LTD

13.7.1 COMPANY SNAPSHOT

13.7.2 REVENUE ANALYSIS

13.7.3 PRODUCT PORTFOLIO

13.7.4 RECENT DEVELOPMENT

13.8 M.C.I. SANTÉ ANIMALE

13.8.1 COMPANY SNAPSHOT

13.8.2 PRODUCT PORTFOLIO

13.8.3 RECENT DEVELOPMENT

13.9 ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC (PYT) LTD

13.9.1 COMPANY SNAPSHOT

13.9.2 PRODUCT PORTFOLIO

13.9.3 RECENT DEVELOPMENTS

14 QUESTIONNAIRE

15 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 VACCINES UNDER CLINICAL TRIAL

TABLE 2 THE SIDE EFFECTS RELATED TO VACCINES

TABLE 3 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY TYPE 2022-2031 (USD THOUSAND)

TABLE 4 MIDDLE EAST AND AFRICA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 5 MIDDLE EAST AND AFRICA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 6 MIDDLE EAST AND AFRICA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 7 MIDDLE EAST AND AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 8 MIDDLE EAST AND AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 9 MIDDLE EAST AND AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 10 MIDDLE EAST AND AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

THE AFRICAN HORSE SICKNESS SEGMENT IS FURTHER SUB-SEGMENTED BY TYPE INTO LIVE AND INACTIVATED. 92

TABLE 11 MIDDLE EAST AND AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 12 MIDDLE EAST AND AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 13 MIDDLE EAST AND AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 14 MIDDLE EAST AND AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 15 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 16 MIDDLE EAST AND AFRICA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 17 MIDDLE EAST AND AFRICA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 18 MIDDLE EAST AND AFRICA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 19 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 20 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 21 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 22 MIDDLE EAST HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 23 MIDDLE EAST HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 24 MIDDLE EAST ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 25 MIDDLE EAST BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 26 MIDDLE EAST BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 27 MIDDLE EAST FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 28 MIDDLE EAST FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 29 MIDDLE EAST AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 30 MIDDLE EAST AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 31 MIDDLE EAST RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 32 MIDDLE EAST RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 33 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 34 MIDDLE EAST HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 35 MIDDLE EAST CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 36 MIDDLE EAST OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 37 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 38 SAUDI ARABIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 39 SAUDI ARABIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 40 SAUDI ARABIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 41 SAUDI ARABIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 42 SAUDI ARABIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 43 SAUDI ARABIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 44 SAUDI ARABIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 45 SAUDI ARABIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 46 SAUDI ARABIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 47 SAUDI ARABIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 48 SAUDI ARABIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 49 SAUDI ARABIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 50 SAUDI ARABIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 51 SAUDI ARABIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 52 SAUDI ARABIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 53 SAUDI ARABIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 54 SAUDI ARABIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 55 EGYPT ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 56 EGYPT HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 57 EGYPT HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 58 EGYPT ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 59 EGYPT BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 60 EGYPT BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 61 EGYPT FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 62 EGYPT FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 63 EGYPT AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 64 EGYPT AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 65 EGYPT RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 66 EGYPT RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 67 EGYPT ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 68 EGYPT HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 69 EGYPT CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 70 EGYPT OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 71 EGYPT ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 72 U.A.E. ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 73 U.A.E. HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 74 U.A.E. HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 75 U.A.E. ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 76 U.A.E. BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 77 U.A.E. BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 78 U.A.E. FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 79 U.A.E. FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 80 U.A.E. AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 81 U.A.E. AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 82 U.A.E. RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 U.A.E. RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 84 U.A.E. ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 85 U.A.E. HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 86 U.A.E. CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 87 U.A.E. OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 88 U.A.E. ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 89 ISRAEL ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 ISRAEL HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 91 ISRAEL HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 92 ISRAEL ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 93 ISRAEL BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 94 ISRAEL BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 95 ISRAEL FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 96 ISRAEL FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 97 ISRAEL AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 98 ISRAEL AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 99 ISRAEL RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 100 ISRAEL RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 101 ISRAEL ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 102 ISRAEL HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 103 ISRAEL CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 104 ISRAEL OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 ISRAEL ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 106 IRAN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 107 IRAN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 108 IRAN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 109 IRAN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 110 IRAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 IRAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 112 IRAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 113 IRAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 114 IRAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 115 IRAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 116 IRAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 117 IRAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 118 IRAN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 119 IRAN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 120 IRAN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 121 IRAN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 122 IRAN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 123 IRAQ ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 124 IRAQ HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 125 IRAQ HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 126 IRAQ ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 127 IRAQ BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 128 IRAQ BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 129 IRAQ FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 130 IRAQ FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 131 IRAQ AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 132 IRAQ AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 133 IRAQ RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 134 IRAQ RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 IRAQ ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 136 IRAQ HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 137 IRAQ CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 138 IRAQ OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 139 IRAQ ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 140 OMAN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 141 OMAN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 142 OMAN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 143 OMAN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 144 OMAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 145 OMAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 146 OMAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 147 OMAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 148 OMAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 149 OMAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 150 OMAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 151 OMAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 152 OMAN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 153 OMAN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 154 OMAN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 155 OMAN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 156 OMAN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 157 KUWAIT ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 158 KUWAIT HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 159 KUWAIT HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 160 KUWAIT ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 161 KUWAIT BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 162 KUWAIT BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 163 KUWAIT FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 164 KUWAIT FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 165 KUWAIT AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 166 KUWAIT AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 167 KUWAIT RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 168 KUWAIT RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 169 KUWAIT ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 170 KUWAIT HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 171 KUWAIT CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 172 KUWAIT OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 173 KUWAIT ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 174 QATAR ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 175 QATAR HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 176 QATAR HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 177 QATAR ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 178 QATAR BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 179 QATAR BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 180 QATAR FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 181 QATAR FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 182 QATAR AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 183 QATAR AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 184 QATAR RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 185 QATAR RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 186 QATAR ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 187 QATAR HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 188 QATAR CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 189 QATAR OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 190 QATAR ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 191 BAHRAIN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 192 BAHRAIN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 193 BAHRAIN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 194 BAHRAIN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 195 BAHRAIN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 196 BAHRAIN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 197 BAHRAIN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 198 BAHRAIN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 199 BAHRAIN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 200 BAHRAIN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 201 BAHRAIN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 202 BAHRAIN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 203 BAHRAIN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 204 BAHRAIN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 205 BAHRAIN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 206 BAHRAIN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 207 BAHRAIN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 208 YEMEN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 209 YEMEN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 210 YEMEN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 211 YEMEN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 212 YEMEN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 213 YEMEN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 214 YEMEN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 215 YEMEN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 216 YEMEN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 217 YEMEN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 218 YEMEN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 YEMEN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 220 YEMEN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 221 YEMEN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 222 YEMEN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 223 YEMEN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 224 YEMEN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 225 JORDAN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 226 JORDAN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 227 JORDAN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 228 JORDAN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 229 JORDAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 230 JORDAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 231 JORDAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 232 JORDAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 233 JORDAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 234 JORDAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 235 JORDAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 236 JORDAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 237 JORDAN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 238 JORDAN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 239 JORDAN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 240 JORDAN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 241 JORDAN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 242 LEBANON ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 243 LEBANON HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 244 LEBANON HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 245 LEBANON ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 246 LEBANON BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 247 LEBANON BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 248 LEBANON FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 249 LEBANON FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 250 LEBANON AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 251 LEBANON AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 252 LEBANON RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 253 LEBANON RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 254 LEBANON ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 255 LEBANON HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 256 LEBANON CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 257 LEBANON OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 258 LEBANON ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 259 PALESTINE ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 260 PALESTINE HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 261 PALESTINE HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 262 PALESTINE ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 263 PALESTINE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 264 PALESTINE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 265 PALESTINE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 266 PALESTINE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 267 PALESTINE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 268 PALESTINE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 269 PALESTINE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 270 PALESTINE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 271 PALESTINE ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 272 PALESTINE HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 273 PALESTINE CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 274 PALESTINE OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 275 PALESTINE ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 276 REST OF MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 277 AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 278 AFRICA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 279 AFRICA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 280 AFRICA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 281 AFRICA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 282 AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 283 AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 284 AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 285 AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 286 AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 287 AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 288 AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 289 AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 290 AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 291 AFRICA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 292 AFRICA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 293 AFRICA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 294 AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 295 SOUTH AFRICA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 296 SOUTH AFRICA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 297 SOUTH AFRICA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 298 SOUTH AFRICA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 299 SOUTH AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 300 SOUTH AFRICA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 301 SOUTH AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 302 SOUTH AFRICA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 303 SOUTH AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 304 SOUTH AFRICA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 305 SOUTH AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 306 SOUTH AFRICA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 307 SOUTH AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 308 SOUTH AFRICA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 309 SOUTH AFRICA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 310 SOUTH AFRICA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 311 SOUTH AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 312 NIGERIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 313 NIGERIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 314 NIGERIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 315 NIGERIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 316 NIGERIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 317 NIGERIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 318 NIGERIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 319 NIGERIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 320 NIGERIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 321 NIGERIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 322 NIGERIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 323 NIGERIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 324 NIGERIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 325 NIGERIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 326 NIGERIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 327 NIGERIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 328 NIGERIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 329 ETHIOPIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 330 ETHIOPIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 331 ETHIOPIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 332 ETHIOPIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 333 ETHIOPIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 334 ETHIOPIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 335 ETHIOPIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 336 ETHIOPIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 337 ETHIOPIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 338 ETHIOPIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 339 ETHIOPIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 340 ETHIOPIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 341 ETHIOPIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 342 ETHIOPIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 343 ETHIOPIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 344 ETHIOPIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 345 ETHIOPIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 346 TANZANIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 347 TANZANIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 348 TANZANIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 349 TANZANIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 350 TANZANIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 351 TANZANIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 352 TANZANIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 353 TANZANIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 354 TANZANIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 355 TANZANIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 356 TANZANIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 357 TANZANIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 358 TANZANIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 359 TANZANIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 360 TANZANIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 361 TANZANIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 362 TANZANIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 363 KENYA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 364 KENYA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 365 KENYA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 366 KENYA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 367 KENYA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 368 KENYA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 369 KENYA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 370 KENYA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 371 KENYA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 372 KENYA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 373 KENYA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 374 KENYA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 375 KENYA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 376 KENYA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 377 KENYA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 378 KENYA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 379 KENYA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 380 ALGERIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 381 ALGERIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 382 ALGERIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 383 ALGERIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 384 ALGERIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 385 ALGERIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 386 ALGERIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 387 ALGERIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 388 ALGERIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 389 ALGERIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 390 ALGERIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 391 ALGERIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 392 ALGERIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 393 ALGERIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 394 ALGERIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 395 ALGERIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 396 ALGERIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 397 GHANA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 398 GHANA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 399 GHANA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 400 GHANA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 401 GHANA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 402 GHANA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 403 GHANA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 404 GHANA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 405 GHANA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 406 GHANA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 407 GHANA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 408 GHANA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 409 GHANA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 410 GHANA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 411 GHANA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 412 GHANA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 413 GHANA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 414 MOZAMBIQUE ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 415 MOZAMBIQUE HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 416 MOZAMBIQUE HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 417 MOZAMBIQUE ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 418 MOZAMBIQUE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 419 MOZAMBIQUE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 420 MOZAMBIQUE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 421 MOZAMBIQUE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 422 MOZAMBIQUE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 423 MOZAMBIQUE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 424 MOZAMBIQUE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 425 MOZAMBIQUE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 426 MOZAMBIQUE ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 427 MOZAMBIQUE HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 428 MOZAMBIQUE CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 429 MOZAMBIQUE OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 430 MOZAMBIQUE ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 431 UGANDA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 432 UGANDA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 433 UGANDA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 434 UGANDA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 435 UGANDA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 436 UGANDA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 437 UGANDA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 438 UGANDA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 439 UGANDA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 440 UGANDA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 441 UGANDA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 442 UGANDA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 443 UGANDA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 444 UGANDA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 445 UGANDA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 446 UGANDA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 447 UGANDA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 448 DEMOCRATIC REPUBLIC OF CONGO ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 449 DEMOCRATIC REPUBLIC OF CONGO HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 450 DEMOCRATIC REPUBLIC OF CONGO HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 451 DEMOCRATIC REPUBLIC OF CONGO ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 452 DEMOCRATIC REPUBLIC OF CONGO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 453 DEMOCRATIC REPUBLIC OF CONGO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 454 DEMOCRATIC REPUBLIC OF CONGO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 455 DEMOCRATIC REPUBLIC OF CONGO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 456 DEMOCRATIC REPUBLIC OF CONGO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 457 DEMOCRATIC REPUBLIC OF CONGO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 458 DEMOCRATIC REPUBLIC OF CONGO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 459 DEMOCRATIC REPUBLIC OF CONGO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 460 DEMOCRATIC REPUBLIC OF CONGO ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 461 DEMOCRATIC REPUBLIC OF CONGO HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 462 DEMOCRATIC REPUBLIC OF CONGO CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 463 DEMOCRATIC REPUBLIC OF CONGO OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 464 DEMOCRATIC REPUBLIC OF CONGO ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 465 SUDAN ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 466 SUDAN HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 467 SUDAN HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 468 SUDAN ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 469 SUDAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 470 SUDAN BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 471 SUDAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 472 SUDAN FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 473 SUDAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 474 SUDAN AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 475 SUDAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 476 SUDAN RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 477 SUDAN ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 478 SUDAN HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 479 SUDAN CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 480 SUDAN OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 481 SUDAN ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 482 MOROCCO ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 483 MOROCCO HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 484 MOROCCO HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 485 MOROCCO ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 486 MOROCCO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 487 MOROCCO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 488 MOROCCO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 489 MOROCCO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 490 MOROCCO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 491 MOROCCO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 492 MOROCCO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 493 MOROCCO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 494 MOROCCO ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 495 MOROCCO HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 496 MOROCCO CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 497 MOROCCO OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 498 MOROCCO ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 499 ANGOLA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 500 ANGOLA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 501 ANGOLA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 502 ANGOLA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 503 ANGOLA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 504 ANGOLA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 505 ANGOLA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 506 ANGOLA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 507 ANGOLA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 508 ANGOLA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 509 ANGOLA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 510 ANGOLA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 511 ANGOLA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 512 ANGOLA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 513 ANGOLA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 514 ANGOLA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 515 ANGOLA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 516 MADAGASCAR ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 517 MADAGASCAR HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 518 MADAGASCAR HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 519 MADAGASCAR ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 520 MADAGASCAR BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 521 MADAGASCAR BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 522 MADAGASCAR FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 523 MADAGASCAR FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 524 MADAGASCAR AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 525 MADAGASCAR AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 526 MADAGASCAR RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 527 MADAGASCAR RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 528 MADAGASCAR ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 529 MADAGASCAR HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 530 MADAGASCAR CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 531 MADAGASCAR OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 532 MADAGASCAR ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 533 MALAWI ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 534 MALAWI HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 535 MALAWI HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 536 MALAWI ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 537 MALAWI BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 538 MALAWI BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 539 MALAWI FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 540 MALAWI FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 541 MALAWI AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 542 MALAWI AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 543 MALAWI RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 544 MALAWI RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 545 MALAWI ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 546 MALAWI HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 547 MALAWI CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 548 MALAWI OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 549 MALAWI ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 550 ZAMBIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 551 ZAMBIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 552 ZAMBIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 553 ZAMBIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 554 ZAMBIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 555 ZAMBIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 556 ZAMBIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 557 ZAMBIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 558 ZAMBIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 559 ZAMBIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 560 ZAMBIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 561 ZAMBIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 562 ZAMBIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 563 ZAMBIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 564 ZAMBIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 565 ZAMBIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 566 ZAMBIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 567 IVORY COAST ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 568 IVORY COAST HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 569 IVORY COAST HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 570 IVORY COAST ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 571 IVORY COAST BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 572 IVORY COAST BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 573 IVORY COAST FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 574 IVORY COAST FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 575 IVORY COAST AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 576 IVORY COAST AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 577 IVORY COAST RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 578 IVORY COAST RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 579 IVORY COAST ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 580 IVORY COAST HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 581 IVORY COAST CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 582 IVORY COAST OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 583 IVORY COAST ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 584 CAMEROON ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 585 CAMEROON HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 586 CAMEROON HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 587 CAMEROON ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 588 CAMEROON BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 589 CAMEROON BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 590 CAMEROON FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 591 CAMEROON FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 592 CAMEROON AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 593 CAMEROON AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 594 CAMEROON RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 595 CAMEROON RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 596 CAMEROON ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 597 CAMEROON HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 598 CAMEROON CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 599 CAMEROON OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 600 CAMEROON ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 601 ZIMBABWE ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 602 ZIMBABWE HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 603 ZIMBABWE HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 604 ZIMBABWE ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 605 ZIMBABWE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 606 ZIMBABWE BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 607 ZIMBABWE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 608 ZIMBABWE FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 609 ZIMBABWE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 610 ZIMBABWE AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 611 ZIMBABWE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 612 ZIMBABWE RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 613 ZIMBABWE ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 614 ZIMBABWE HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 615 ZIMBABWE CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 616 ZIMBABWE OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 617 ZIMBABWE ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 618 LIBYA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 619 LIBYA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 620 LIBYA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 621 LIBYA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 622 LIBYA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 623 LIBYA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 624 LIBYA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 625 LIBYA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 626 LIBYA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 627 LIBYA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 628 LIBYA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 629 LIBYA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 630 LIBYA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 631 LIBYA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 632 LIBYA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 633 LIBYA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 634 LIBYA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 635 CHAD ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 636 CHAD HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 637 CHAD HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 638 CHAD ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 639 CHAD BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 640 CHAD BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 641 CHAD FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 642 CHAD FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 643 CHAD AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 644 CHAD AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 645 CHAD RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 646 CHAD RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 647 CHAD ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 648 CHAD HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 649 CHAD CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 650 CHAD OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 651 CHAD ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 652 BOTSWANA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 653 BOTSWANA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 654 BOTSWANA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 655 BOTSWANA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 656 BOTSWANA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 657 BOTSWANA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 658 BOTSWANA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 659 BOTSWANA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 660 BOTSWANA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 661 BOTSWANA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 662 BOTSWANA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 663 BOTSWANA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 664 BOTSWANA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 665 BOTSWANA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 666 BOTSWANA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 667 BOTSWANA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 668 BOTSWANA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 669 NAMIBIA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 670 NAMIBIA HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 671 NAMIBIA HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 672 NAMIBIA ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 673 NAMIBIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 674 NAMIBIA BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 675 NAMIBIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 676 NAMIBIA FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 677 NAMIBIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 678 NAMIBIA AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 679 NAMIBIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 680 NAMIBIA RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 681 NAMIBIA ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 682 NAMIBIA HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 683 NAMIBIA CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 684 NAMIBIA OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 685 NAMIBIA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 686 LESOTHO ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 687 LESOTHO HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 688 LESOTHO HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 689 LESOTHO ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 690 LESOTHO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 691 LESOTHO BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 692 LESOTHO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 693 LESOTHO FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 694 LESOTHO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 695 LESOTHO AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 696 LESOTHO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 697 LESOTHO RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 698 LESOTHO ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 699 LESOTHO HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 700 LESOTHO CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 701 LESOTHO OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 702 LESOTHO ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 703 MAURITIUS ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 704 MAURITIUS HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 705 MAURITIUS HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 706 MAURITIUS ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 707 MAURITIUS BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 708 MAURITIUS BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 709 MAURITIUS FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 710 MAURITIUS FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 711 MAURITIUS AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 712 MAURITIUS AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 713 MAURITIUS RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 714 MAURITIUS RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 715 MAURITIUS ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 716 MAURITIUS HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 717 MAURITIUS CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 718 MAURITIUS OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 719 MAURITIUS ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 720 ESWATINI ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 721 ESWATINI HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 722 ESWATINI HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 723 ESWATINI ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 724 ESWATINI BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 725 ESWATINI BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 726 ESWATINI FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 727 ESWATINI FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 728 ESWATINI AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 729 ESWATINI AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 730 ESWATINI RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 731 ESWATINI RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 732 ESWATINI ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 733 ESWATINI HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 734 ESWATINI CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 735 ESWATINI OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 736 ESWATINI ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 737 COMOROS ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 738 COMOROS HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 739 COMOROS HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 740 COMOROS ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 741 COMOROS BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 742 COMOROS BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 743 COMOROS FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 744 COMOROS FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 745 COMOROS AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 746 COMOROS AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 747 COMOROS RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 748 COMOROS RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 749 COMOROS ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 750 COMOROS HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 751 COMOROS CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 752 COMOROS OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 753 COMOROS ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 754 SEYCHELLES ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

TABLE 755 SEYCHELLES HUMAN IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 756 SEYCHELLES HUMAN PAPILLOMAVIRUS (HPV) IN ANIMAL AND HUMAN VACCINES MARKET, BY DISEASE INDICATION, 2022-2031 (USD THOUSAND)

TABLE 757 SEYCHELLES ANIMAL IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 758 SEYCHELLES BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 759 SEYCHELLES BRUCELLOSIS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 760 SEYCHELLES FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 761 SEYCHELLES FOOT AND MOUTH IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 762 SEYCHELLES AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 763 SEYCHELLES AFRICAN HORSE SICKNESS IN ANIMAL AND HUMAN VACCINES MARKET, BY ANIMAL, 2022-2031 (USD THOUSAND)

TABLE 764 SEYCHELLES RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 765 SEYCHELLES RIFT VALLEY FEVER IN ANIMAL AND HUMAN VACCINES MARKET, BY VACCINE TYPE, 2022-2031 (USD THOUSAND)

TABLE 766 SEYCHELLES ANIMAL AND HUMAN VACCINES MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 767 SEYCHELLES HOSPITALS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 768 SEYCHELLES CLINICS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 769 SEYCHELLES OTHERS IN ANIMAL AND HUMAN VACCINES MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 770 SEYCHELLES ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 771 REST OF AFRICA ANIMAL AND HUMAN VACCINES MARKET, TYPE, 2022-2031 (USD THOUSAND)

Abbildungsverzeichnis

FIGURE 1 INDIA AND EUROPE GENERIC INJECTABLES MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: SEGMENTATION

FIGURE 10 ESCALATING INCIDENCE OF CHRONIC DISEASES AND SURGE IN THE DEVELOPMENT AND PRODUCTION OF VACCINES ARE DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 11 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET IN 2024 AND 2031

FIGURE 12 OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET

FIGURE 13 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY TYPE, 2023

FIGURE 14 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY TYPE, 2024-2031 (USD THOUSAND)

FIGURE 15 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 16 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY TYPE, LIFELINE CURVE

FIGURE 17 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY END USER, 2023

FIGURE 18 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 19 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY END USER, CAGR (2024-2031)

FIGURE 20 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY END USER, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 22 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 23 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 24 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 25 MIDDLE EAST &AFRICA ANIMAL AND HUMAN VACCINES MARKET: SNAPSHOT (2023)

FIGURE 26 MIDDLE EAST ANIMAL AND HUMAN VACCINES MARKET: SNAPSHOT (2023)

FIGURE 27 AFRICA ANIMAL AND HUMAN VACCINES MARKET: SNAPSHOT (2023)

FIGURE 28 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET: COMPANY SHARE 2023 (%)

Detaillierte Informationen anzeigen Right Arrow

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The Middle East and Africa animal and human vaccines market size will be worth USD 5,358,452.80 thousand by 2031.
The growth rate of the Middle East and Africa animal and human vaccines market is 5.6%.
The latest developments in the Middle East and Africa animal and human vaccines market are - In January 2023, Senvelgo, the recent innovation from Boehringer Ingelheim, has secured the prestigious Animal Health Best New Product for Companion Animals award & Merck & Co., Inc. received approval from the U.S. Food and Drug Administration (FDA) for KEYTRUDA, its anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for treating patients with FIGO 2014 Stage III-IVA cervical cancer.
Type, end user, and distribution channel are the factors on which the Middle East and Africa animal and human vaccines market research is based.
Growing immunization programs and campaigns & growing prevalence of chronic conditions are the growth drivers of the Middle East and Africa animal and human vaccines market.